It's good news but... one of the last paragraphs....
"We are hoping to carry out trials over the coming years to develop
such a treatment that could potentially greatly improve the lives of
people living with ALS."
"over the coming years."
Maybe this will trigger some other existing research much sooner.
Thanks Laurie for your dedication to more/new information.
Biogen has a Phase I trial going with an agent that targets ataxin-2, which in turn targets toxicity of TDP-43, that shows an active recruitment status.